Literature DB >> 28884501

Procalcitonin, erythrocyte sedimentation rate and C-reactive protein in acute pulmonary exacerbations of cystic fibrosis.

Geoffrey Loh1, Ilya Ryaboy2, Andrew Skabelund1, Alicia French3.   

Abstract

INTRODUCTION: Acute pulmonary exacerbations of cystic fibrosis (APECF) are a leading cause of morbidity and mortality among patients with cystic fibrosis (CF). APECF require frequent administration of antibiotics and subsequently lead to development of resistant organisms.
OBJECTIVES: The aim of this study was to identify inflammatory markers that may be help identify need for antibiotics and exacerbation as well as predict risk of exacerbations.
METHODS: A total of 17 patients were enrolled, and baseline erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and procalcitonin levels were obtained in addition to obtaining these levels during admissions for APECF.
RESULTS: A total of 28 APECF were recorded. ESR and CRP significantly increased during exacerbation (P < .01 for both). Procalcitonin did not increase during exacerbations. Baseline elevations in ESR and CRP increased risk of an exacerbation (RR = 2.3 and 4.5, respectively).
CONCLUSIONS: ESR and CRP are useful markers for CF exacerbations, as levels rise with exacerbations. Baseline elevations in ESR and CRP were noted to show an increased risk for CF exacerbations. Procalcitonin, in contrast, is not a useful inflammatory marker.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  acute exacerbation; bronchiectasis; cystic fibrosis; inflammation

Mesh:

Substances:

Year:  2017        PMID: 28884501     DOI: 10.1111/crj.12703

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  3 in total

1.  C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response.

Authors:  D R VanDevanter; S L Heltshe; M Skalland; N E West; D B Sanders; C H Goss; P A Flume
Journal:  J Cyst Fibros       Date:  2021-12-18       Impact factor: 5.527

2.  Procalcitonin predicts the severity of cystic fibrosis pulmonary exacerbations and readmissions in adult patients: a prospective cohort study.

Authors:  Kristina L Bailey; Peter J Murphy; Olena K Lineberry; Matthew R Haack; John D Dickinson; Andre C Kalil
Journal:  J Investig Med       Date:  2020-01-21       Impact factor: 2.895

3.  CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis.

Authors:  Katherine B Hisert; Timothy P Birkland; Kelly Q Schoenfelt; Matthew E Long; Brenda Grogan; Suzanne Carter; W Conrad Liles; Edward F McKone; Lev Becker; Anne M Manicone; Sina A Gharib
Journal:  Front Pharmacol       Date:  2020-08-13       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.